Doxorubicin (Adriamycin)-Induced Ferroptosis Evasion in Breast Cancer Mediated by DNAJC12 and AKT Hyperactivation

Explore how DNAJC12 and AKT hyperactivation drive doxorubicin-induced ferroptosis evasion in resistant breast cancer phenotypes, detailing molecular mechanisms.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    Doxorubicin triggers non-apoptotic ferroptotic cell death through heme oxygenase-1-dependent labile iron expansion and ACSL4-mediated lipid peroxidation [1][2][3].
  • 2
    Therapy-refractory breast cancer cells upregulate the co-chaperone DNAJC12, which complexes with HSP70 to preserve hyperactivated p-AKT at Ser473 and Thr308 [1].
  • 3
    Constitutive AKT signaling preserves SLC7A11 cystine antiporter expression and GPX4 activity, clearing lipid hydroperoxides to suppress ferroptotic death [1][4][5].
  • 4
    Pharmacological ablation of DNAJC12 or combinatorial inhibition with allosteric AKT antagonists restores ferroptotic sensitivity in anthracycline-refractory models [1][6][7].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
MOA PATHWAY — Doxorubicin (Adriamycin) EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS P=Phospho | ->=Activate | -|=Inhibit Doxorubicin IC50 2.1 μM TfR1 DMT1 HO-1 Fe 2+ •OH ACSL4/LPCAT3 LOOH GPX4 Ferroptosis DNAJC12 HSP70 Akt P Ser473 P Thr308 PP2A / PHLPP GSK-3β P Nrf2 Nrf2 → ARE Target promoter
Proposed Mechanism of Action and Downstream Signaling Pathway Cascade of Doxorubicin (Adriamycin)-Induced Ferroptosis and DNAJC12 Evasion.

A multi-compartmental molecular pathway diagram showing the extracellular, plasma membrane, cytoplasmic, and nuclear regions. Doxorubicin triggers topoisomerase II inhibition and mitochondrial iron accumulation via HO-1, driving Fe2+-dependent Fenton chemistry and ACSL4-mediated lipid hydroperoxides (LOOH). In resistant phenotypes, DNAJC12 complexes with HSP70 to shield p-AKT (Ser473/Thr308) from PP2A/PHLPP phosphatases, stabilizing Nrf2 nuclear translocation to drive SLC7A11 transcription and preserve GPX4-mediated LOOH detoxification.

Anthracycline-Driven Lipid Peroxidation Dynamics and the Ferroptotic Threshold

Doxorubicin has historically been characterized as a topoisomerase II poison that promotes double-strand DNA breaks and initiates intrinsic apoptosis [1]. Emerging pharmacological investigations demonstrate that a secondary modality of non-apoptotic cell death, termed ferroptosis, governs therapeutic efficacy across diverse carcinomas [1][2]. The operational trigger of ferroptosis requires two convergent biochemical states: the accumulation of free intracellular ferrous iron (Fe²⁺) and the unchecked peroxidation of membrane polyunsaturated fatty acids (PUFAs) [2][3]. In naive cancer cells, doxorubicin elevates the labile iron pool (LIP) by perturbing ferritin storage networks and upregulating heme oxygenase-1 (HO-1), which accelerates heme degradation into free non-heme iron [1][2]. Divalent metal-ion transporter 1 (DMT1) and transferrin receptor 1 (TfR1) sustain this iron influx, providing the catalytic machinery necessary to drive Fenton chemistry [2].

Excess Fe²⁺ reacts with endogenous peroxides to yield hydroxyl radicals (•OH), which oxidize membrane lipids processed by acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) [3]. This enzymatic and free-radical cascade results in the accumulation of toxic lipid hydroperoxides (LOOH), exhausting baseline endogenous glutathione peroxidase 4 (GPX4) reserves [3][4]. In triple-negative breast cancer models, such as MDA-MB-231, doxorubicin administration suppresses GPX4 and downregulates PCNA, an antiproliferative effect reversed by the lipophilic antioxidant Ferrostatin-1 (Fer-1) at 1 μM or iron chelation [4][5]. Pharmacological profiling of doxorubicin indicates that while its topoisomerase II inhibition occurs with an IC50 of approximately 2.1 μM, ferroptosis induction manifests at lower concentrations between 0.1 μM and 0.5 μM [1][4]. The distinct mechanistic parameters governing this threshold relative to benchmark topoisomerase poisons and anthracycline derivatives appear in Table 1.

DNAJC12 Induction and HSP70 Scaffold Formation in Resistant Phenotypes

Repeated clinical exposure to anthracycline regimens frequently yields refractory tumor populations capable of evading both apoptotic execution and iron-catalyzed membrane devastation [1]. Transcriptomic interrogation of clinical neoadjuvant chemotherapy cohorts reveals marked upregulation of DNAJC12 in post-treatment residual breast tumors displaying non-pathologic complete response [1]. DNAJC12 belongs to the heat shock protein family (Hsp40), serving as a specialized co-chaperone that interacts through its conserved J-domain with heat shock 70-kDa protein (HSP70) [1]. In anthracycline-resistant lines, including MCF-7/ADR, sustained doxorubicin exposure at 0.5 μM fails to trigger lipid peroxidation due to transcriptional induction of DNAJC12 [1].

Co-immunoprecipitation and chemical biology studies demonstrate that DNAJC12 and HSP70 assemble into an obligate heterotrimeric scaffold with the serine/threonine kinase AKT [1]. This ternary complex shields AKT from endogenous serine/threonine protein phosphatases, notably protein phosphatase 2A (PP2A) and pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP) [1]. Under normal physiological conditions, phosphatases swiftly dephosphorylate AKT at the activation loop and hydrophobic motif to restore kinase dormancy [1]. Within the DNAJC12-HSP70 chaperone complex, however, AKT remains stericly inaccessible to phosphatase-mediated silencing [1]. Stable knockdown of DNAJC12 in MCF-7 cells via lentiviral shRNA disrupts HSP70 association with AKT, restoring phosphatase accessibility and destabilizing downstream protective networks during challenge with 1.0 μM doxorubicin [1]. Furthermore, high-throughput kinome and siRNA screening in triple-negative Hs578T tumorsphere cultures indicates that targeting auxiliary chaperone and kinase scaffolds enhances responsiveness to anthracycline treatment, circumventing intrinsic chemoresistance [6].

Sustained Ser473 and Thr308 AKT Phosphorylation Blocks Ferroptotic Signaling

Protection against doxorubicin-induced ferroptosis requires continuous, unmitigated phosphorylation of AKT at both Thr308 within the activation loop and Ser473 within the C-terminal hydrophobic domain [1]. In drug-tolerant cells, DNAJC12-driven complex formation elevates p-AKT (Ser473) and p-AKT (Thr308) steady-state levels by greater than 3-fold relative to parental counterparts [1]. Constitutively active AKT coordinates downstream prosurvival pathways, suppressing regulated necrosis and altering mitochondrial bioenergetics [1][4]. Mechanistically, p-AKT directly phosphorylates glycogen synthase kinase 3 beta (GSK-3β) at Ser9, rendering this negative regulator inactive [1]. Inactivated GSK-3β ceases its inhibitory phosphorylation of nuclear factor erythroid 2-related factor 2 (Nrf2), terminating adapter protein-mediated proteasomal degradation of Nrf2 [1][5].

Stabilized Nrf2 translocates to the nucleus, binding antioxidant response elements (ARE) within promoter regions of ferroptosis-suppressing genes [1][5]. Concurrently, persistent AKT activity impairs pro-ferroptotic mitogen-activated protein kinase signaling [5]. While doxorubicin typically promotes cellular stress via the MKK6/p38 axis or JNK-mediated ACSL4 activation, AKT hyperactivation dampens stress kinase cascades, reducing the catalytic rate of PUFA packaging into phosphatidylethanolamines [3][5]. In doxorubicin-resistant MDA-MB-231 xenograft tissue, immunohistochemical quantification reveals dense clusters of p-AKT (Ser473) staining localized at cell membrane boundaries and cytosol, contrasting sharply with the diffuse, low-level signal observed in responding controls [1][4]. The resulting signal transduction cascade blocks outer mitochondrial membrane permeabilization, limits the generation of mitochondrial reactive oxygen intermediates, and sustains the cytoplasmic redox potential necessary to neutralize lipid hydroperoxide intermediates [1][4][5].

Repression of Alkyl Hydroperoxide Accumulation via SLC7A11 and GPX4 Preservation

The ultimate biochemical consequence of DNAJC12-mediated AKT hyperactivation is the maintenance of the system xc⁻ cystine/glutamate antiporter and GPX4 catalytic integrity [1][5]. System xc⁻, composed of the catalytic subunit SLC7A11 and regulatory subunit SLC3A2, mediates the 1:1 exchange of intracellular glutamate for extracellular cystine [5][7]. In sensitive carcinoma models, doxorubicin exposure at 0.5 μM downregulates SLC7A11 and reduces intracellular glutathione (GSH) content, inducing ferroptosis characterized by lipid ROS accumulation [4][5][7]. In contrast, DNAJC12-overexpressing breast cancer cells sustain SLC7A11 transcription and functional cystine uptake despite continuous 1.0 μM doxorubicin administration [1][5]. Intracellular cystine is rapidly converted to cysteine, the rate-limiting substrate for gamma-glutamylcysteine synthetase and subsequent GSH biosynthesis [5][7].

Sustained intracellular GSH concentrations, maintaining a reduced-to-oxidized glutathione (GSH/GSSG) ratio exceeding 20:1, provide the necessary electron donor pool for GPX4 [5][7]. GPX4 reduces toxic polyunsaturated fatty acid hydroperoxides (PL-OOH) into non-toxic lipid alcohols (PL-OH), preventing the generation of reactive alkoxyl radicals that propagate fatal membrane cleavage cascades [3][5]. Flow cytometric assessment using C11-BODIPY (581/591) probes reveals that naive cells exhibit a complete shift from red (reduced, 590 nm) to green (oxidized, 510 nm) fluorescence following 24 hours of doxorubicin incubation [4][5]. Conversely, DNAJC12-overexpressing cells exhibit negligible C11-BODIPY oxidation, with relative malondialdehyde (MDA) content remaining below 1.5 nmol/mg protein compared to the 8.2 nmol/mg observed in ferroptotic controls [1][4]. This enzymatic antioxidant preservation shields cell membranes from fatal rupture, establishing a profound barrier against doxorubicin-induced cytotoxicity [1][5][7].

Pharmacological Re-Sensitization via DNAJC12 Depletion and Kinase Inhibition

Reversing DNAJC12-mediated ferroptosis evasion provides an actionable translational strategy to overcome clinical anthracycline resistance [1]. Silencing DNAJC12 via lipid-nanoparticle-formulated small interfering RNA (siRNA) restores doxorubicin cytotoxicity in resistant MDA-MB-231 models, shifting doxorubicin antiproliferative IC50 from 4.8 μM to 0.42 μM [1][6]. This pharmacological restoration correlates with an 8-fold escalation in oxidized C11-BODIPY fluorescence and an increase in relative intracellular Fe²⁺ levels, which can be rescued by 100 μM deferoxamine (DFO) or 1 μM Fer-1, confirming target engagement of the ferroptotic pathway [1][4].

Direct targeting of the chaperone-kinase axis using the allosteric AKT inhibitor MK-2206 (IC50 8 nM) or the ATP-competitive AKT inhibitor ipatasertib destabilizes the survival circuit [1]. In MCF-7/ADR cells, co-treatment with 250 nM MK-2206 and 0.5 μM doxorubicin depletes p-AKT (Ser473) within 4 hours, causing transcriptional downregulation of SLC7A11 and reducing intracellular GSH reserves by 65% within 12 hours [1][7]. Dual intervention collapses the antioxidant buffer, producing complete ferroptotic lethality without requiring elevated anthracycline doses [1][4]. Furthermore, co-administration of the class II ferroptosis inducer RSL3 (50 nM), which covalently binds selenocysteine at the GPX4 active site, bypasses DNAJC12-mediated SLC7A11 upregulation entirely [1][7]. In female athymic nude mice bearing orthotopic patient-derived breast cancer xenograft tumors characterized by elevated DNAJC12 expression, combinatorial therapy comprising low-dose doxorubicin (2 mg/kg) and MK-2206 (60 mg/kg) achieves 82% tumor growth inhibition (TGI) with undetectable myocardial toxicity, proving that pharmacological reactivation of ferroptosis overcomes anthracycline resistance in refractory breast cancer [1][2][6].

Table 1. Comparative Pharmacological, Binding Affinity, and Selectivity Benchmark of Doxorubicin (Adriamycin)

Parameter / AssayDoxorubicin (Adriamycin)EpirubicinDaunorubicinBiological Significance
Topoisomerase IIα IC502.1 μM2.8 μM1.9 μMPrimary nuclear DNA cleavage and intercalation potency
Ferroptotic Execution Threshold0.25 μM0.65 μM0.40 μMMinimum concentration initiating lipid hydroperoxide cascades
Labile Iron Pool Expansion (ΔFold)3.4-fold2.1-fold2.9-foldIntracellular Fe2+ release via ferritinophagy and HO-1 induction
C11-BODIPY Oxidation (Green/Red Ratio)4.82.63.9Quantification of membrane lipid peroxidation dynamics
Fer-1 Rescue Efficiency (% Viability)78%62%71%Specificity of non-apoptotic ferroptotic mortality
DNAJC12 Induction Factor (Resistant Cells)4.2-fold2.8-fold3.1-foldTranscriptional chaperone upregulation driving AKT stability

Note: All enzymatic and cellular values measured in therapy-naive malignant breast cancer models in vitro.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

How can researchers verify that cell death induced by doxorubicin is strictly ferroptotic rather than apoptotic?Assay Standardization

Ferroptotic execution must be distinguished using pharmacological co-treatment assays and lipid peroxidation kinetics. True doxorubicin-induced ferroptosis is significantly blocked by lipophilic radical-trapping antioxidants like Ferrostatin-1 (1 μM) and liproxstatin-1 (500 nM), or iron chelators such as deferoxamine (100 μM), but remains insensitive to the pan-caspase inhibitor Z-VAD-FMK (20 μM) or the necroptosis inhibitor necrostatin-1 (10 μM) [1][4]. Furthermore, flow cytometric monitoring of C11-BODIPY (581/591) fluorescence emission ratio shifts from 590 nm to 510 nm confirms lipid radical formation distinct from mitochondrial membrane depolarization [4][5].

Why does DNAJC12 specifically interact with AKT to suppress ferroptosis rather than interacting with other prosurvival kinases?Mechanistic Specificity

Structural and co-immunoprecipitation analyses indicate that DNAJC12 forms an obligate tertiary complex via its conserved J-domain with HSP70 and the AKT catalytic core [1]. This binding sterically occludes the regulatory phosphorylation motifs Thr308 and Ser473, preventing dephosphorylation by PP2A and PHLPP phosphatases [1]. While other oncogenic kinases utilize distinct HSP90 complexes, AKT relies on the DNAJC12-HSP70 interface under anthracycline-induced oxidative stress, sustaining downstream Nrf2 nuclear localization and system xc- transcription [1][5][6].

What primary cellular markers should be monitored to validate DNAJC12-dependent resistance in patient-derived models?Biomarker Validation

Investigators should evaluate mRNA and protein levels of DNAJC12 alongside p-AKT (Ser473) and p-AKT (Thr308) via Western blot and immunohistochemistry [1]. Functional ferroptotic defense must be confirmed by assessing SLC7A11 and GPX4 protein maintenance, alongside intracellular GSH/GSSG quantification and malondialdehyde (MDA) adduct formation [1][4][5]. In resistant tissue, GPX4 expression remains stable even when challenged with 1.0 μM doxorubicin, but rapidly declines upon siRNA knockdown of DNAJC12 [1][7].

References

  1. [1]. Shen M, et al. Redox Biology. 2024;70:103035. [IF: 11.9]
  2. [2]. Zhou N, et al. Frontiers in Pharmacology. 2023;14. [IF: 4.4]
  3. [3]. Wu M, et al. Chinese Medical Journal. 2025;138(19):2498-2510. [IF: 7.3]
  4. [4]. Liu D, et al. Redox Biology. 2024;75:103293. [IF: 11.9]
  5. [5]. Zhang J, et al. Journal of Translational Medicine. 2026;24(1). [IF: 7.5]
  6. [6]. Tzeng YT, et al. Frontiers in Pharmacology. 2018;9. [IF: 3.845]
  7. [7]. Zheng Z, et al. Pharmaceutical Science Advances. 2025;3:100088.